145 results about "Aggresome" patented technology

The invention discloses a chimera for degrading a CARD structural domain protein aggregate and application of the chimera. The chimera is prepared from light-operated targeting protein and light-operated degradation protein, the light-operated targeting protein is sequentially connected by an MAVS CARD structural domain, a flexible connecting peptide and a photosensitive protein pMag; the light-controlled degradation protein is sequentially connected by a photosensitive protein nMag, a flexible connecting peptide and an RING structural domain of TRIM21. According to the application, a light-operated activated CARD-RING chimera is constructed, and when the CARTAC generates toxic and side effects or in cells with RIG-I / MDA5 signal channels abnormally activated, the activity of the CARTAC can be effectively controlled or autoimmune diseases caused by RIG-I / MDA5 abnormity can be inhibited.

The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides peptides, compositions, adsorbents, and related methods, capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from samples during the production and purification of adenovirus.

The invention belongs to the technical field of enzyme engineering and gene engineering, and particularly relates to a recombinant immobilized enzyme, an expression gene thereof and application of the recombinant immobilized enzyme in production of macrocyclodextrin. According to the preparation method, SpyTag and SpyCatcher peptides are fused to the N end of isoamylase and the N end of 4-alpha-glucanotransferase respectively, the 4-alpha-glucanotransferase modified by the SpyTag and the isoamylase modified by the SpyCatcher are obtained, and after spontaneous isopeptide bonds are formed between the SpyTag and the SpyCatcher, the self-assembled macrocyclodextrin production enzyme cluster is obtained. The obtained macrocyclodextrin production enzyme cluster forms an enzyme aggregate with a three-dimensional structure under the traditional glutaraldehyde-mediated catalytic action, namely the recombinant immobilized enzyme. The recombinant immobilized enzyme disclosed by the invention can be repeatedly utilized, is simple and convenient to operate, is easy to separate a converted product, and can be applied to industrial production of the macrocyclodextrin.

The present disclosure provides materials and methods related to the purification of a biologic from a biological fluid. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production of a biologic.

The present disclosure relates generally to compositions, systems, and methods for lysing blood samples comprising an infectious agent, for example a bacteria, or a fungus, while maintaining viability of the infectious agent for subsequent characterization, for example phenotyping or genotyping. A lysing composition may include one or more surfactants, such as one or more detergents. A lysing composition may include lysing agent including one or more salts. A lysing composition may include one or more enzymes to break down one or more lyses byproducts, such as nucleic acids and / or protein aggregates.

Novel and useful compounds, such as 2,4-dihydropyrazolo[3',4':4,5]pyrano[2,3-b]pyridines, are disclosed herein. Such compounds may be employed in various treatments, alleviation, or prevention of a group of disorders, such as disorders associated with Tau (tubulin associated unit) protein aggregates, such as neurofibrillary tangles (NFTs), such as Alzheimer's disease (AD).

The invention relates to methods and materials for use in treating neurodegenerative diseases associated with pathological protein aggregates and provides fusion proteins comprising: (i) a first portion comprising a sequence of a protein which aggregates pathologically in neurodegenerative disease, such as tau protein, and (ii) a second portion comprising a RING-type E3 ubiquitin ligase, a component of a RING-type E3 ubiquitin ligase complex, or a domain of either. These fusion proteins have utility in selectively or preferentially targeting pathogenic protein aggregates for degradation.

The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production and purification of adeno-associated viruses (AAVs).

This invention provides a ready-to-drink milk tea based on a ternary complex stabilized with κ-casein genotype and its preparation method, belonging to the field of dairy processing technology. It includes a ternary complex of casein micelles containing AA genotype κ-casein, epigallocatechin gallate, and fructose. The preparation of the ready-to-drink milk tea includes the following steps: S1: raw material screening and pretreatment; S2: preparation of the ternary complex; S3: blending and processing of the ready-to-drink milk tea. By screening AA genotype κ-casein raw milk and using a specific sequence of first compounding EGCG and then grafting fructose, a casein micelle-EGCG-fructose ternary complex with uniform structure and controllable particle size is constructed. Fructose is further grafted onto the surface of the complex through glycosylation, effectively masking the excessive binding sites of proteins and polyphenols, significantly inhibiting the formation of insoluble aggregates, thereby maintaining excellent colloidal stability of the product during its shelf life.

A method for determining the presence of soluble, misfolded protein in or on the eye of a subject is described. The method includes contacting the eye of the subject with a monomeric protein to form an incubation mixture; incubating the incubation mixture to form a misfolded protein aggregate from the monomeric protein; and determining if a detectable amount of misfolded and / or aggregated protein is present in or on the eye; wherein detection of misfolded and / or aggregated protein indicates the presence of soluble, misfolded protein in the eye. Use of the method for diagnosing disease associated with protein misfolding in a subject is also described.

An object of the present invention is to provide a cell aggregate-inducing peptide, a cell aggregate-forming agent containing the same, and a method for forming a cell aggregate using the same.SOLUTION: A cell aggregate-inducing peptide represented by General Formula (1), having hydroxypipecolic acid and lysine as constituent repeating units. (HPA-Lys) n. (1) [In the general formula (1), HPA represents hydroxypipecolic acid, Lys represents lysine, and n is an integer of 4 or more and 30 or less.]. ] SELECTED DRAWING: None

This invention discloses a method for preparing a secondary antibody and its application, belonging to the fields of biomedicine and bioengineering technology. The invention specifically designs an efficient multidimensional chromatographic purification strategy, sequentially passing the serum to be purified through four chromatographic columns: affinity capture (recovering IgG target molecules and removing most plasma protein impurities); antigen affinity enrichment (further enriching antibody subpopulations with high affinity and specificity to the target antigen, reducing the coexistence of non-specific subpopulations); tandem cross-adsorption (removing antibody subpopulations that cross-react to non-target species and reducing potential non-specific binding); and size exclusion / gel filtration (removing high molecular weight aggregates and low molecular weight residues, and achieving final buffer replacement and sample homogenization). The secondary antibody prepared by this invention exhibits significantly better sensitivity, specificity, and batch-to-batch consistency than existing technologies, with sensitivity improved by approximately 57% and specificity greatly enhanced compared to conventional techniques.

The invention relates to a method of detecting cancer in a subject based on the level of p53 protein aggregates in a body fluid sample from the subject. The invention also relates to corresponding methods of determining the risk of cancer in a subject, monitoring the progression or onset of cancer, and / or determining the efficacy of a therapeutic intervention for treating cancer in a subject. The invention further relates to kits for use said methods.

The invention belongs to the technical field of antibody purification, and relates to a method for removing impurities in a sample containing a trispecific antibody. According to the method provided by the invention, impurities, especially aggregates and fragments, can be well removed, and the purity detected by molecular exclusion chromatography-high performance liquid chromatography (SEC-HPLC) is increased from about 74% to 98% or above; the purity detected by non-reduction method lauryl sodium sulfate capillary electrophoresis (NR-CE-SDS) is improved from about 76% to 93% or above. Besides, the method provided by the invention can control the content of host cell protein at a lower level, greatly improves the quality of a tri-specific antibody product, and has the advantages of stable process and easiness in large-scale production.

Disclosed are compositions and methods for treating Alzheimer's disease or for use in treating Alzheimer's disease. Also disclosed are compositions and methods for treating or for use in treating a neurodegenerative disorder characterized by the presence of tau protein aggregates. Furthermore, disclosed are compositions and methods for reducing tau protein aggregates or for use in reducing tau protein aggregates.

Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

The application discloses application of TRIM11 protein in preparation of a medicine for treating spinocerebellar ataxia 51. The application adopts an SCA51 specific cell model, and identifies, through a large number of screening experiments, that the TRIM11 protein has the function of significantly removing mutant THAP11 protein and aggregates thereof. Experimental data show that the mutant protein removal efficiency of the TRIM11 treatment group is significantly better than that of the control group. The application verifies the removal effect of TRIM11 on the SCA51 pathological protein from the two dimensions of protein expression level and subcellular localization through Western blotting quantitative analysis and immunofluorescence co-localization technology. The three-dimensional reconstruction image clearly shows that the mutant protein aggregates are significantly reduced. The application first establishes a complete research system from target discovery to mechanism analysis, and provides a new intervention strategy for precise treatment of SCA51.

The present application belongs to the field of biosensors, and relates to a dual-mode sensor for detecting BACE1, in particular to a dual-mode sensor for detecting BACE1 and a preparation method and application thereof. The present application first uses silver nanoparticles co-modified by luminol and short peptides as an electrochemiluminescence and electrochemical dual-mode signal unit, uses a three-dimensional aggregate formed by CB[8] induced aggregation of silver nanoparticles co-modified by luminol and short peptides P2 as a signal probe, carries out signal labeling and signal amplification, and thus improves the sensitivity of BACE1 activity detection. It is worth noting that the dual-mode sensor provides diversified analysis data for the detection of BACE1 activity, and shows high selectivity and repeatability. Compared with a single-mode sensor, the dual-mode sensor can significantly improve the analysis efficiency and accuracy, and has important scientific significance and application value.

The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.

The present invention relates to a method and system (140) for determining the presence and / or quantity of protein aggregates in a liquid sample comprising a protein. The method comprises: a) measuring ultraviolet-visible spectroscopy (UV- Vis) absorbance of the sample to obtain a UV-Vis absorbance measurement; b) measuring index of refraction (IoR) of the sample to obtain an IoR measurement; c) determining a value for the UV-Vis absorbance measurement; d) determining a value for the IoR measurement; and e) determining the presence and / or quantity of protein aggregates in the sample based on a ratio between the value for the UV-Vis absorbance measurement and the value for the IoR measurement.

Methods and compositions for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARα expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction. Also provided are methods of treating peripheral metabolic dysfunction associated with neurodegenerative conditions.

Provided are: a compound that imparts protein adhesion properties to cells; a method, using the compound, for producing cells having protein adhesion properties; cells adsorbed by the compound; and a cell sheet, a cell aggregation (spheroid, tumor-like body, etc.), an organoid, a three-dimensional tissue, etc. comprising the cells.

The invention discloses an amyloid-like protein-based nano-pesticide, the nano-pesticide is a nano-particle with a core-shell structure, an outer shell material is a nano-film obtained by modifying protein and then unfolding and assembling, and a core layer is a drug aggregate. The drug aggregate is prepared through a solvent exchange method, then protein is induced to be rapidly self-assembled by using a modifier, and a phase-transition protein nano-film is formed to be rapidly adhered to the surface of the drug self-assembled aggregate. The obtained amyloid-like protein-based nano-pesticide product has excellent performances in the aspects of ultraviolet shielding performance, leaf adhesion and deposition, insecticidal activity, safety and the like, pesticide can be accurately conveyed in a target spot manner, the bioavailability of the pesticide is effectively improved, the environmental pollution is reduced, and the sustainable development of agriculture is promoted.

The present invention relates to an in vitro method for detecting the β-sheet aggregate form of a protein that forms β-sheet aggregates (PAFβ) in a sample, comprising the steps of adjusting the pH of a sample likely to contain PAFβ to a pH in the range of 9.7 to 13.2, and measuring the PNAFβ content using a suitable immunological method at a pH in the range of 6 to 9, in order to isolate all or a portion of the PAFβ to obtain the β-sheet non-aggregated form of a protein that forms β-sheet aggregates (PNAFβ).

The invention discloses a method for preparing a high-protein solution from hydrophobin through membrane treatment and ultrasonic assistance, and belongs to the technical field of food protein modification and membrane separation. The preparation method comprises the following steps: dispersing hydrophobic protein in an alkaline solution, adding maltodextrin into the alkaline solution, carrying out multiple times of concentration and dilution operation through membrane treatment to remove salt ions and macromolecular aggregates, and then adjusting the pH value of a solution system to be neutral by adopting an acidic solution; the preparation method comprises the following steps: firstly, preparing a solution, then treating the solution under the ultrasonic action to form a micro-nano particle structure with good colloidal stability, and finally, concentrating and drying to obtain powdery protein with high solubility. The soluble protein powder obtained by the invention can be widely applied to vegetable protein drinks, nutritional formula foods and functional foods.

The invention discloses an improved optimization process for improving yeast fermentation expression protein, which is characterized in that through dynamic temperature-pH coupling control and synergistic improvement of culture medium components, foreign protein expression quantity (gt, 90%) and biological activity (gt, 100%) are remarkably improved, and protein aggregate formation is reduced. The process has high magnification and is suitable for the field of biological pharmacy.

The present invention relates to compounds suitable for imaging TDP-43 (transactive response (TAR) DNA-binding protein 43 kDa) aggregates. The compounds can be used, for example, to diagnose diseases, disorders, or abnormalities associated with TDP-43 aggregates or TDP-43 proteinopathies, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), frontotemporal dementia (FTD), and limbic-predominant late-stage TDP-43 encephalopathy (LATE).

Compositions and methods for disrupting pathological aggregation and / or mis-localization of TDP-43 in the brain / CNS have been developed. Compositions including engineered helical polypeptides that bind TDP-43's amyloidogenic core but resist β-sheet conversion are provided. In some forms, the engineered polypeptides include peptide degradation motifs (PDM) to enhance proteolytic degradation of aggregates, and / or targeting motifs to direct the peptides to the brain / CNS. Recombinant constructs including nucleic acids expressing or encoding the polypeptides are also provided. Methods of using the engineered peptides to treat or prevent one or more diseases or disorders associated with pathological aggregation and / or mis-localization of TDP-43 in the brain / CNS are also provided. In some forms, the methods treat or prevent ALS or FTD in a subject in need thereof.

The application provides a method for rapidly preparing multi-size alpha-synuclein aggregates, and solves the problems of complicated steps and high cost in the prior art method for preparing alpha-synuclein aggregates of different sizes. The method comprises the following steps: 1) dissolving and uniformly mixing the separated and purified alpha-synuclein monomers in a physiological buffer solution to obtain a monomer protein solution; 2) placing the monomer protein solution in a centrifugal tube, and shaking and incubating under certain conditions, and sampling at different time points in the incubation process; 3) adding the samples into ultrafiltration centrifugal tubes, and centrifuging and separating to remove small-size proteins; 4) adding a physiological buffer solution into the ultrafilters of the ultrafiltration centrifugal tubes, and inverting the ultrafilters into centrifugal tubes matched with the ultrafilters, centrifuging and separating to collect the protein aggregates on the membranes in the ultrafilters, and obtaining protein aggregates of different morphological structures.

The present invention relates to a use of extracellular vesicles derived from three-dimensional spheroid-type cell aggregates prepared by a method of the present invention for preventing, ameliorating or treating inflammatory skin diseases. It was demonstrated that the extracellular vesicles derived from three-dimensional spheroid-type cell aggregates according to the present invention suppress the expression of inflammatory cytokines and restore skin barrier-related proteins in animal models of atopic dermatitis. This indicates that the extracellular vesicles of the present invention simultaneously improve immune homeostasis and the skin barrier, and thus may be widely used in the fields of prevention, amelioration, and treatment of inflammatory dermatitis.